跳至主要内容
临床试验/ISRCTN57761809
ISRCTN57761809已完成不适用

Effect of anti-tumour necrosis factor alpha (TNFa) therapy on endothelial function and other surrogate markers of cardiovascular disease in patients with rheumatoid arthritis

niversity of Dundee (UK)0 个研究点目标入组 90 人开始时间: 2008年5月9日最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
发起方
入组人数
90

研究概览

简要总结

暂无简介。

研究设计

研究类型
Observational

入排标准

性别
All

入选标准

  • 1. Both males and females, 18 years old or over
  • 2. Fulfil the 1987 American College of Rheumatology (ACR) classification criteria for rheumatoid arthritis
  • 3. No exposure to anti-TNFa drugs in the last 3 months
  • 4. Fulfil the National Institute for Clinical Excellence guidelines on the use of anti-TNFa drugs in rheumatoid arthritis* and be:
  • 4.1. About to start etanercept or adalimumab (treatment group)
  • 4.2. About to start methotrexate (control group)
  • * The patients in the control group must have had adequate therapeutic trial of at least one previous Disease Modifying Anti-Rheumatic Drug (DMARD) rather than two

排除标准

  • 1. Previous cardiovascular or cerebrovascular event in the last 3 years
  • 2. Undergoing treatment for a cardiovascular risk factor except:
  • 2.1. Patients with hypertension on stable medication for the last 3 months
  • 2.2. Patients with hypercholesterolaemia on stable medication for the last 3 months

研究者

发起方
niversity of Dundee (UK)

相似试验